JP2022514499A5 - - Google Patents

Info

Publication number
JP2022514499A5
JP2022514499A5 JP2021533517A JP2021533517A JP2022514499A5 JP 2022514499 A5 JP2022514499 A5 JP 2022514499A5 JP 2021533517 A JP2021533517 A JP 2021533517A JP 2021533517 A JP2021533517 A JP 2021533517A JP 2022514499 A5 JP2022514499 A5 JP 2022514499A5
Authority
JP
Japan
Prior art keywords
cdr2
seq
nos
cdr3 sequences
sequences described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533517A
Other languages
English (en)
Japanese (ja)
Other versions
JP7535045B2 (ja
JP2022514499A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053036 external-priority patent/WO2020123011A1/en
Publication of JP2022514499A publication Critical patent/JP2022514499A/ja
Publication of JP2022514499A5 publication Critical patent/JP2022514499A5/ja
Priority to JP2024077880A priority Critical patent/JP7805395B2/ja
Application granted granted Critical
Publication of JP7535045B2 publication Critical patent/JP7535045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533517A 2018-12-13 2019-09-25 抗il-27抗体及びその使用 Active JP7535045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077880A JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779341P 2018-12-13 2018-12-13
US62/779,341 2018-12-13
PCT/US2019/053036 WO2020123011A1 (en) 2018-12-13 2019-09-25 Anti-il-27 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077880A Division JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2022514499A JP2022514499A (ja) 2022-02-14
JP2022514499A5 true JP2022514499A5 (cg-RX-API-DMAC7.html) 2022-10-20
JP7535045B2 JP7535045B2 (ja) 2024-08-15

Family

ID=71075792

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533517A Active JP7535045B2 (ja) 2018-12-13 2019-09-25 抗il-27抗体及びその使用
JP2024077880A Active JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077880A Active JP7805395B2 (ja) 2018-12-13 2024-05-13 抗il-27抗体及びその使用

Country Status (14)

Country Link
US (2) US12358978B2 (cg-RX-API-DMAC7.html)
EP (1) EP3894440A4 (cg-RX-API-DMAC7.html)
JP (2) JP7535045B2 (cg-RX-API-DMAC7.html)
KR (1) KR102933484B1 (cg-RX-API-DMAC7.html)
CN (1) CN113544151B (cg-RX-API-DMAC7.html)
AU (1) AU2019399474B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011393A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121420A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191666A1 (cg-RX-API-DMAC7.html)
IL (1) IL283875A (cg-RX-API-DMAC7.html)
MA (1) MA54469A (cg-RX-API-DMAC7.html)
MX (1) MX2021006980A (cg-RX-API-DMAC7.html)
SG (1) SG11202105161YA (cg-RX-API-DMAC7.html)
WO (1) WO2020123011A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途
CA3151078A1 (en) * 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
US12240897B2 (en) * 2020-09-22 2025-03-04 Institute For Cancer Research Treatment of non-alcoholic steatohepatitis (NASH) with IL-27 antibody
AU2022270170A1 (en) * 2021-05-07 2023-09-21 Surface Oncology, LLC Anti-il-27 antibodies and uses thereof
WO2023230116A1 (en) * 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) * 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240052047A1 (en) * 2022-08-03 2024-02-15 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
WO2024097641A2 (en) * 2022-11-01 2024-05-10 Surface Oncology, LLC Methods of treating a tumor
WO2026055167A1 (en) * 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055168A1 (en) * 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20050214296A1 (en) 2004-02-17 2005-09-29 Schering Corporation Methods of modulating cytokine activity; related reagents
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
WO2012097238A2 (en) * 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
WO2018075740A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途

Similar Documents

Publication Publication Date Title
JP2022050618A5 (cg-RX-API-DMAC7.html)
JP6345787B2 (ja) 抗ang2抗体とcd40アゴニストとの併用療法
HRP20220014T1 (hr) Postupci liječenja raka kože davanjem inhibitora pd-1
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2019515008A5 (cg-RX-API-DMAC7.html)
FI3618863T3 (fi) Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
JP2023543152A5 (cg-RX-API-DMAC7.html)
DK2608808T3 (en) TREATMENT OF NEOPLASTIC DISEASES
RU2019104980A (ru) Анти-icos антитела
JP7801225B2 (ja) 抗tnfr2抗体及びその使用
JP7138094B2 (ja) マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
US20220396623A1 (en) Uses of anti-icos antibodies
CN110981958A (zh) 一种pd-l1抗体
WO2015119841A1 (en) Role of il-23 and pd-1 in autoreactive immune response
JP2022523804A (ja) がんの処置における増強された有効性のためのil-4/il-13経路阻害剤
JP2022512384A5 (cg-RX-API-DMAC7.html)
CN117980336A (zh) 抗tnfr2抗体及其用途
KR20240038991A (ko) 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합
US20250340641A1 (en) Uses of anti-icos antibodies
TW202104263A (zh) 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案
CN119997974A (zh) 一种异源二聚体融合蛋白及其应用
KR20230048112A (ko) Cd40 효능성 항체 및 이의 사용 방법
JP2023512151A5 (cg-RX-API-DMAC7.html)
CN114616245A (zh) 一种抗cd38的抗体及其用途
CN118542937A (zh) 抗αvβ3抗体和抗PD-1抗体的联合药物